HRP20030858A2 - Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency - Google Patents

Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency

Info

Publication number
HRP20030858A2
HRP20030858A2 HR20030858A HRP20030858A HRP20030858A2 HR P20030858 A2 HRP20030858 A2 HR P20030858A2 HR 20030858 A HR20030858 A HR 20030858A HR P20030858 A HRP20030858 A HR P20030858A HR P20030858 A2 HRP20030858 A2 HR P20030858A2
Authority
HR
Croatia
Prior art keywords
potency
manufacturing
pharmaceutical composition
low dose
drug distribution
Prior art date
Application number
HR20030858A
Other languages
English (en)
Inventor
Scott Gierer Daniel
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HRP20030858A2 publication Critical patent/HRP20030858A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20030858A 2001-05-01 2003-10-21 Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency HRP20030858A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28784101P 2001-05-01 2001-05-01
PCT/IB2002/000766 WO2002087546A2 (en) 2001-05-01 2002-03-13 Method for manufacturing a low dose pharmaceutical composition

Publications (1)

Publication Number Publication Date
HRP20030858A2 true HRP20030858A2 (en) 2005-08-31

Family

ID=23104578

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030858A HRP20030858A2 (en) 2001-05-01 2003-10-21 Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency

Country Status (44)

Country Link
US (2) US7037530B2 (xx)
EP (1) EP1383482B1 (xx)
JP (1) JP2004531537A (xx)
KR (1) KR100568380B1 (xx)
CN (1) CN1240375C (xx)
AP (1) AP2003002900A0 (xx)
AR (1) AR033288A1 (xx)
AT (1) ATE367152T1 (xx)
AU (1) AU2002236166B2 (xx)
BG (1) BG108297A (xx)
BR (1) BR0209283A (xx)
CA (1) CA2445519C (xx)
CZ (1) CZ20032959A3 (xx)
DE (1) DE60221238T2 (xx)
DK (1) DK1383482T3 (xx)
DO (1) DOP2002000389A (xx)
EA (1) EA005949B1 (xx)
EC (1) ECSP034826A (xx)
EE (1) EE200300537A (xx)
ES (1) ES2286226T3 (xx)
GE (1) GEP20053654B (xx)
GT (1) GT200200078A (xx)
HK (1) HK1065705A1 (xx)
HR (1) HRP20030858A2 (xx)
HU (1) HUP0401391A3 (xx)
IL (1) IL158390A0 (xx)
IS (1) IS6985A (xx)
MA (1) MA27017A1 (xx)
MX (1) MXPA03009391A (xx)
NO (1) NO20034709L (xx)
NZ (1) NZ528886A (xx)
OA (1) OA12596A (xx)
PA (1) PA8544401A1 (xx)
PE (1) PE20021137A1 (xx)
PL (1) PL366453A1 (xx)
PT (1) PT1383482E (xx)
SK (1) SK286536B6 (xx)
TN (1) TNSN03106A1 (xx)
TW (1) TWI264311B (xx)
UA (1) UA75135C2 (xx)
UY (1) UY27277A1 (xx)
WO (1) WO2002087546A2 (xx)
YU (1) YU81503A (xx)
ZA (1) ZA200307819B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009259A (es) 2002-03-28 2005-01-25 Pfizer Prod Inc Lasofoxifeno racemico purificado y d-tartrato de lasofoxifeno purificado y un metodo para la purificacion efectiva del lasofoxifeno racemico.
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US7444197B2 (en) 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
EP2023745A1 (en) * 2006-05-17 2009-02-18 WM. Wrigley Jr., Company Method of preparing a food product
FI20070521L (fi) 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
FI20080351A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
US8951562B2 (en) 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
US20100179110A1 (en) * 2006-12-20 2010-07-15 Mostafa Akbarieh Composition Containing a Bisphosphonic Acid in Combination with Vitamin D
US20080181972A1 (en) * 2007-01-29 2008-07-31 Valentina Amico Compositions and Methods for Maintaining, Strengthening, Improving, or Promoting Eye Health
ES2603617T3 (es) 2007-02-23 2017-02-28 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de la terapéutica
KR101784647B1 (ko) 2008-05-02 2017-10-11 길리애드 사이언시즈, 인코포레이티드 제약 제제의 가공성 향상을 위한 고체 담체 입자의 용도
EP2291233B1 (en) * 2008-05-09 2019-09-04 Atacama Labs Oy Method for dry granulation
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
EA029996B1 (ru) 2008-06-06 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Капсулярная лекарственная форма, содержащая суспензионную композицию производного индолинона
ES2520990T3 (es) * 2009-01-29 2014-11-12 Ucb Pharma, S.A. Composiciones farmacéuticas que comprenden derivados de 2-oxo-1-pirrolidina
CN104083328B (zh) * 2009-01-29 2017-04-12 Ucb生物制药私人有限公司 包含2‑氧代‑1‑吡咯烷衍生物的药物组合物
US20140350945A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America System and Method for Validation of Pharmaceutical Composition Formulations
CN103830196A (zh) * 2014-03-14 2014-06-04 王志刚 一种酒石酸拉索昔芬分散片及其制备方法
CN106176649B (zh) * 2016-08-31 2020-04-17 北京斯利安药业有限公司 叶酸vb12片及其制备方法
MX2019009777A (es) * 2017-02-17 2019-10-14 Massachusetts Inst Technology Sistemas y metodos para la fabricacion de tabletas, que incluyen tabletas farmaceuticas.
CZ309820B6 (cs) * 2021-04-23 2023-11-08 Pro.Med.Cs Praha A.S. Způsob přípravy pevné lékové formy obsahující kompozici s nízkým obsahem účinné látky

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725555A (en) * 1967-08-01 1973-04-03 Ciba Geigy Corp Bactericidal compositions and method of killing bacteria using bis-(phenoxyphenyl) carbonates
US3725556A (en) * 1970-11-12 1973-04-03 D Hanssen Method of manufacturing rapidly disintegrating pharmaceutical tablets
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
GB1570993A (en) * 1976-05-21 1980-07-09 Fisons Ltd Pharmaceutical tablet formulation
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US5004613A (en) * 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US5107331A (en) * 1989-03-07 1992-04-21 The Color Group Method and apparatus for producing half-tone separations at the same screen angle
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US5976570A (en) * 1993-12-21 1999-11-02 Applied Analytical Industries, Inc. Method for preparing low dose pharmaceutical products
US5928668A (en) * 1993-12-21 1999-07-27 Applied Analytical Industries, Inc. Method for dry blend compression of medicaments
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
US5733578A (en) * 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
JPH10204082A (ja) * 1996-10-25 1998-08-04 Eli Lilly & Co 選択的エストロゲンレセプターモジュレーターとしての活性を有する置換されたベンゾ［ｂ］チオフェン化合物
US6080427A (en) * 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
EP0889056B1 (en) * 1997-07-01 2006-04-12 Pfizer Products Inc. Process for making a cyclodextrin
US6300367B1 (en) * 1999-04-20 2001-10-09 Protein Technologies International, Inc. Composition for and method of preventing or treating breast cancer
US6555551B1 (en) * 1999-08-31 2003-04-29 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos

Also Published As

Publication number Publication date
MA27017A1 (fr) 2004-12-20
ES2286226T3 (es) 2007-12-01
ZA200307819B (en) 2004-10-07
HK1065705A1 (en) 2005-03-04
ATE367152T1 (de) 2007-08-15
CA2445519C (en) 2009-01-20
EA200301040A1 (ru) 2004-04-29
MXPA03009391A (es) 2004-01-29
IS6985A (is) 2003-10-09
CN1240375C (zh) 2006-02-08
DE60221238T2 (de) 2007-10-31
HUP0401391A3 (en) 2009-06-29
BR0209283A (pt) 2004-07-13
GEP20053654B (en) 2005-11-10
CA2445519A1 (en) 2002-11-07
AR033288A1 (es) 2003-12-10
US7037530B2 (en) 2006-05-02
TNSN03106A1 (fr) 2005-12-23
US20060093667A1 (en) 2006-05-04
AP2003002900A0 (en) 2003-12-31
CN1531423A (zh) 2004-09-22
NO20034709D0 (no) 2003-10-21
OA12596A (en) 2006-06-08
PE20021137A1 (es) 2002-12-14
DOP2002000389A (es) 2002-11-30
IL158390A0 (en) 2004-05-12
WO2002087546A3 (en) 2003-02-13
BG108297A (bg) 2005-07-29
EP1383482A2 (en) 2004-01-28
NZ528886A (en) 2005-04-29
SK13552003A3 (sk) 2004-09-08
UA75135C2 (en) 2006-03-15
CZ20032959A3 (cs) 2004-01-14
GT200200078A (es) 2003-01-31
PL366453A1 (en) 2005-02-07
KR20040015226A (ko) 2004-02-18
SK286536B6 (sk) 2008-12-05
PT1383482E (pt) 2007-09-20
US7176221B2 (en) 2007-02-13
JP2004531537A (ja) 2004-10-14
AU2002236166B2 (en) 2006-12-07
US20030004182A1 (en) 2003-01-02
HUP0401391A2 (hu) 2004-12-28
EE200300537A (et) 2004-04-15
WO2002087546A2 (en) 2002-11-07
TWI264311B (en) 2006-10-21
YU81503A (sh) 2006-08-17
DK1383482T3 (da) 2007-10-29
NO20034709L (no) 2003-10-31
EP1383482B1 (en) 2007-07-18
EA005949B1 (ru) 2005-08-25
PA8544401A1 (es) 2003-07-28
ECSP034826A (es) 2004-02-26
KR100568380B1 (ko) 2006-04-05
UY27277A1 (es) 2002-11-29
DE60221238D1 (de) 2007-08-30

Similar Documents

Publication Publication Date Title
HRP20030858A2 (en) Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
HUP0203198A3 (en) Pharmaceutical composition comprising a tramadol material and an anticonvulsant drug, process for its preparation and its use
IL149224A0 (en) Hydrogen-driven drug dosage form
HK1053259A1 (en) A method and dosage form for dispensing a bioactive substance
HUP0303891A3 (en) Pharmaceutically active piridine derivatives, process for their preparation and pharmaceutical compositions containing them
IL154012A0 (en) Hydrogel-driven drug dosage form
GB0117618D0 (en) Pharmaceutical dosage form
HUP0301325A3 (en) Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition
PL396568A1 (pl) Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna, farmaceutyczna postać dawkowania, doustna postać dawkowania, zastosowanie oraz sposób wytwarzania krystalicznego bursztynianu O-demetylo-wenlafaksyny
EP1478345A4 (en) NOVEL PHARMACEUTICAL DOSAGE FORMS AND PROCESS FOR PRODUCTION OF SAID DOSAGE FORMS
EP1365747A4 (en) PHARMACEUTICAL PRESENTATION OF ORAL PEPTIDE ADMINISTERED AND METHOD OF PRODUCTION
AU2001283563A1 (en) Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
IL200849A0 (en) Pharmaceutical composition comprising bisphosphonate for oral application and a process for its prepatrtion
AU2002319653A1 (en) Method for oral drug delivery
AU1724301A (en) Hydrogel-driven layered drug dosage form
AU9223098A (en) Dosage form comprising means for changing drug delivery shape
GB0117619D0 (en) Pharmaceutical dosage form
HK1066459A1 (en) Pharmaceutical dosage form and method of making
IL162666A0 (en) A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
HUP0302050A3 (en) Pharmaceutical form of administration for peptides, method for its production and use
IL145188A0 (en) Processes for making pharmaceutical oral ecb formulations and compositions
IL161143A0 (en) A flash-melt pharmaceutical oral dosage composition
HUP0303860A3 (en) A pharmaceutical tablet having a high active ingredient
AU2001286725A1 (en) A combinatorial method for rapid screening of drug delivery formulations
HUP0004573A3 (en) New camptothecin analogue compounds, a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn